The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
An exoskeleton is skeleton that covers the body of an animal, serving as armor to protect an animal from predators. Arthropods have exoskeletons that encase their bodies, and have to undergo periodic moulting or ecdysis as the animals grow. The shells of molluscs are another form of exoskeleton. Exoskeletons provide surfaces for the attachment of muscles, and specialized appendanges of the exoskeleton can assist with movement and defense. In arthropods, the exoskeleton also assists with sensory perception. An external skeleton can be quite heavy in relation to the overall mass of an animal, so on land, organisms that have an exoskeleton are mostly relatively small. Somewhat larger aquatic animals can support an exoskeleton because weight is less of a consideration underwater. The southern giant clam, a species of extremely large saltwater clam in the Pacific Ocean, has a shell that is massive in both size and weight. Syrinx aruanus is a species of sea snail with a very large shell.
=== Incidental discovery === Approximately 30% of adrenal gland carcinomas are diagnosed incidentally (incidentalomas). However, the probability that an adrenal gland incidentaloma is a carcinoma of the adrenal cortex is very low. Adenomas are much more common in this situation. Other benign or malignant tumors can also be the underlying cause.
== Natural sources of alkylresorcinols == Alkylresorcinols are relatively rare in nature and are reported to be found in fungi, bacteria, and some lower and higher plants. DB-2073 is an antibiotic isolated from the broth culture of Pseudomonas sp. They are also the main constituents of the outer shell of the cyst of Azotobacter. Among the plant sources, the shell oil of cashew nut (Anacardium occidentale L.) has the highest amount of ARs, which consists of 20% phenolic lipids. Moreover, ARs were found in the peels and pulp of peas (Pisum sativum L.), pulp and leaves of ginkgo (Ginkgo biloba L.), pulp and peels of mango (Mangifera indica L.), and in some cereals. In the case of cereals, the hyaline layer, inner pericarp, and testa showed the highest amounts of AR.
=== Cell rest of Malassez === These groups of epithelial cells become located in the mature PDL after the disintegration of Hertwig epithelial root sheath during the formation of the root. They form a plexus that surrounds the tooth. Cell rests of Malassez might proliferate during inflammation which may lead to radicular cyst formation in later life.
Sources: en.wikipedia.org
SISCAPA’s use of proteolytic digestion as a first step eliminates the protein:protein complexes (including complexes of a target protein with auto-antibodies) that cause “interferences” in protein capture assays, including conventional immunoassays (e.g., ELISA assays). Elimination of such autoantibody interferences drove the adoption of SISCAPA as an alternative to immunoassays for clinical measurement of thyroglobulin as a marker of thyroid cancer recurrence in patients who exhibit anti-thyroglobulin autoantibodies. A limitation of the specific peptide capture approach is the requirement for a specially developed antibody against the selected peptide. To date several hundred anti-peptide antibody reagents have been developed for enrichment of tryptic peptides from sample digests, mainly for established clinical biomarkers (,) and cancer research targets, but these do not yet cover a majority of protein targets of interest in non-cancer research or clinical contexts. A variety of MS instrument types have been used for quantitation of the enriched peptides, including most frequently triple quadrupole mass spectrometers implementing the “multiple reaction monitoring” (MRM) method (a format sometimes referred to as “immuno-MRM”), and MALDI-ToF (a format sometimes referred to as iMALDI).
==== Water cleaning technology ==== In 2017 the RingwooditE Co Ltd was formed in order to explore Thermonuclear Trap Technology (TTT) for the purpose of cleaning all sources of water from pollution and toxic contents. This patented nanotechnology uses a high pressure and temperature chamber to separate isotopes that should by nature not be in drinking water to pure drinking water, as to the by the WHO´s established classification. This method has been developed by among others, by professor Vladimir Afanasiew, at the Moscow Nuclear Institution. This technology is targeted to clean Sea, river, lake and landfill waste waters. It even removes radioactive isotopes from the sea water, after Nuclear Power Stations catastrophes and cooling water plant towers. By this technology pharmaca rests are being removed as well as narcotics and tranquilizers. Bottom layers and sides at lake and rivers can be returned, after being cleaned. Machinery used for this purpose are much similar to those of deep sea mining. Removed waste items are being sorted by the process, and can be re used as raw material for other industrial production.
Small activating RNAs (saRNAs) are short double-stranded RNA molecules (typically 19–21 nucleotides in length) that induce transcriptional activation of target genes through a process known as RNA activation (RNAa). Unlike RNA interference (RNAi), which silences gene expression, saRNAs upregulate gene expression by targeting promoter regions of DNA and recruiting transcriptional machinery. The mechanism of RNAa involves the formation of an RNA-induced transcriptional activation (RITA) complex. This complex includes Argonaute proteins (particularly Ago2), RNA helicase A (RHA), and other transcriptional coactivators, which facilitate the activation of RNA polymerase II at the targeted promoter. This process is often associated with epigenetic changes, such as histone modifications, that promote active transcription. saRNAs have demonstrated potential in preclinical studies for treating diseases caused by insufficient gene expression, such as cancer and metabolic disorders. For example, saRNAs have been used to reactivate tumor suppressor genes in cancer cells, offering a promising therapeutic approach. Additionally, saRNAs are being explored for their ability to upregulate genes involved in metabolic regulation, neurodegenerative diseases, and other conditions. An example of an saRNA therapeutic in clinical development is MTL-CEBPA, which targets the CEBPA gene to treat liver cancer. This drug, developed by MiNA Therapeutics, has shown promise in early-phase clinical trials.
Sources: en.wikipedia.org
=== Cancer treatment side effects === LLLT has been studied as a way to reduce pain and swelling in breast-cancer related lymphedema. The 2015 systematic review and meta-analysis by Smoot, Chiavola-Larson, et al found "Moderate-strength evidence supports LLLT in the management of [breast cancer related lymphoedema], with […] reductions in volume and pain immediately after conclusion of LLLT treatments. Greater reductions in volume [of lymph nodes or surrounding tissues] were found with the use of LLLT than in treatments without it."
In general, polymeric mixtures are far less miscible than mixtures of small molecule materials. This effect results from the fact that the driving force for mixing is usually entropy, not interaction energy. In other words, miscible materials usually form a solution not because their interaction with each other is more favorable than their self-interaction, but because of an increase in entropy and hence free energy associated with increasing the amount of volume available to each component. This increase in entropy scales with the number of particles (or moles) being mixed. Since polymeric molecules are much larger and hence generally have much higher specific volumes than small molecules, the number of molecules involved in a polymeric mixture is far smaller than the number in a small molecule mixture of equal volume. The energetics of mixing, on the other hand, is comparable on a per volume basis for polymeric and small molecule mixtures. This tends to increase the free energy of mixing for polymer solutions and thereby making solvation less favorable, and thereby making the availability of concentrated solutions of polymers far rarer than those of small molecules. Furthermore, the phase behavior of polymer solutions and mixtures is more complex than that of small molecule mixtures.
=== Metabolism === Among the many metabolic processes in which it participates, glutathione is required for the biosynthesis of leukotrienes and prostaglandins. It plays a role in cysteine storage. Glutathione enhances the function of citrulline as part of the nitric oxide cycle. It is a cofactor and acts on glutathione peroxidase. Glutathione facilitates metabolism of xenobiotics. Glutathione S-transferase enzymes catalyze its conjugation to lipophilic xenobiotics, facilitating their excretion or further metabolism. The conjugation process is illustrated by the metabolism of N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is a reactive metabolite formed by the action of cytochrome P450 on paracetamol (acetaminophen). Glutathione conjugates to NAPQI, and the resulting ensemble is excreted. As a result of this reaction, cellular glutathione concentration tends to be depleted in the presence of acetaminophen.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.